Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
In preclinical models, Dihexa demonstrated superior pharmacokinetic properties, including good oral activity and effective BBB penetration, along with enhanced metabolic stability with a half-life of 335.5 minutes
In diseases like asthma and ARDS, dysregulated arginine metabolism characterized by increased ADMA levels and reduced NO production, leads to epithelial dysfunction and increased oxidative stress
This is normal for a compound at this stage, and it is still a limitation
These factors amplify your results significantly
Overall survival with osimertinib in resected EGFR-mutated NSCLC
US$ 22.49
US$ 27.26
US$ 21.32
.png)
